Regencell Bioscience Holdings (Regencell Bioscience Holdings) Net Income From Continuing Operations

: $-6.06 Mil (TTM As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Regencell Bioscience Holdings's net income from continuing operations for the six months ended in Jun. 2023 was $-2.75 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Jun. 2023 was $-6.06 Mil.

Regencell Bioscience Holdings Net Income From Continuing Operations Historical Data

The historical data trend for Regencell Bioscience Holdings's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regencell Bioscience Holdings Annual Data

Trend

Jun19

Jun20

Jun21

Jun22

Jun23

Net Income From Continuing Operations

-0.39

-0.81

-1.35

-7.60

-6.06

Regencell Bioscience Holdings Semi-Annual Data
	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Net Income From Continuing Operations					-1.01	-3.66	-3.94	-3.32	-2.75

Regencell Bioscience Holdings Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-6.06 Mil.

Regencell Bioscience Holdings (Regencell Bioscience Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Regencell Bioscience Holdings Ltd (NAS:RGC) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

N/A

Address

29 Leighton Road, 9/F Chinachem Leighton Plaza, Causeway Bay, Hong Kong, HKG

Website

https://www.regencellbioscience.com

Regencell Bioscience Holdings Ltd is engaged in the research, development and commercialization of traditional Chinese medicine. The medicines are used for the treatment of neurocognitive disorders and degeneration.